






Pituitary transcription factors in the immunohistochemical 
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Abstract 
Introduction: Although histopathology remains in the first line of the diagnosis of pituitary pathology, immunohistochemistry and mo-
lecular biology are currently in charge of providing a more accurate characterisation of tumours in this field. 
Material and methods: A systematic review of the literature was performed, using the PubMed and SCOPUS databases, with terms that 
included transcription factors involved in the development of pituitary tumours: T-PIT, PIT-1, and SF-1. 
Results: The results showed different perspectives, but the evidence is in favour of a multifold immunohistochemical analysis that must 
include pituitary transcription factors for a highly accurate diagnosis, prognosis, and guidance of (multimodal) therapy. 
Conclusions: By using transcription factors, the understanding of the structure and function of the recently defined pituitary neuroen-
docrine tumours has made significant progress. This approach brings the (sub)classification of pituitary tumours, using cell types and cell 
lineages, with clinical and molecular implications and therapeutic results. (Endokrynol Pol 2021; 72 (1): 53–63)
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Introduction 
Although known as being of monoclonal origin, sev-
eral studies showed that pituitary adenomas (PAs) 
have more than one cell type [1] and contain tumour 
clones that arise independently from individual cells 
[2]. There is a debated hypothesis about the existence 
of self-renewing sphere-forming cells, which resemble 
cancer stem cells and can also be considered as a sign of 
cell differentiation [3]. The supposed multipotent cells 
contained by the PAs are responsible for the growth, in-
vasion, and resistance to specific therapy, being capable 
of differentiating into other cell types of the tumour [4, 5].
In 2017, the World Health Organisation (WHO) 
revised the classification of tumours of endocrine or-
gans [6] and established more clear groups of primary 
adenohypophyseal tumours, concerning their cell lin-
eages and resulting in a better way to classify these tu-
mours. In consequence, the lineage transcription factors 
(TFs) have been proposed to be used in the diagnosis, 
associated with the clinical and imaging characteristics, 
immunohistochemistry of hormones, proliferation fac-
tors, and other specific markers. 
The term pituitary neuroendocrine tumour (PitNET) 
was proposed to replace the term adenoma [7], based 
on the resemblance and unpredictable behaviour with 
extra-pituitary NETs, terminology considered rather 
confusing and debatable by other experts [8]. A mul-
tistep approach of these tumours is necessary. Besides 
the clinical and radiological characteristics, it is relevant 
to prepare a histological report that includes histology, 
immunohistochemistry (IHC) analysis (hormones, 
cytokeratin low-molecular-weight keratin (LMWK) 
pattern, proliferation markers, chromogranin A), TFs, 
and, if required, p53, somatostatin receptors (SSTRs), 
oestrogen receptor alpha (Era), and methylation of 
O6-methylguanine-methyltransferase (MGMT) [9]. 
Validated on 1470 patients in four studies, the five-tiered 
classification proposed by the European Pituitary 
Pathology Group (EPPG) identifies seven main mor-
phological and functional PAs types and has a defined 
prognostic value [10]. 
Although recent protocols for multimodal treatment 
of (functional) PAs have improved the control of the 
disease and the cure rate [11], the need for extensive 
and specific diagnosis is always required. 
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factor 1 (SF-1) and pituitary adenoma (Fig. 1). Cited 
references within articles were also searched for rel-
evancy to the topic. The results were summarised, and 
the following article presents a critical discussion of the 
most significant results. Table 1 summarises the studies 
included in the review that evaluated a minimum of 30 
patients and their main disclosures.
Exclusion criteria were as follows: (1) reviews, (2) 
case reports, (3) letters to editor, (4) editorials, (5) com-
mentaries, (6) animal models, and (7) in vitro studies.
Material and methods
We followed the PRISMA (preferred reporting items for 
systematic reviews and meta-analyses, 2015) guidelines 
in the literature review process.
In the present review, a comprehensive literature 
search was performed using PubMed and SCOPUS 
databases, from January 2000 to June 2020, with the 
following key words: (i) T-PIT and pituitary adenoma, 
(ii) PIT-1 and pituitary adenoma, and (iii) steroidogenic 
















Records after duplicates removed
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Full-text articles assessed for eligibility
(n = 82)





ed Scientific articles included in the review
(n = 72)
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Table 1. Studies included in the review that evaluated at least thirty patients and their main disclosures
Study details Year No. of patients
Studied 
TFs Method Relevant findings
Sano T. 
et al. [76] 2003 46
T-PIT
SF-1
RT-PCR “Honeycomb Golgi” vacuolar aspect can appear in corticotroph (T-PIT lineage) and gonadotroph (SF-1 lineage) PAs
Suzuki M. 






Aberrant TFs T-PIT and SF-1 function synergic during tumorigenesis
PAs that express ACTH and a-subunit may derive from ACTH-committed 
progenitor cells, set up with T-PIT, NeuroD1, SF-1 and DAX-1
Null cell PAs also express various TFs
Cooper O. 





SCAs were positive for ACTH, SF-1, NeuroD1, DAX-1, but T-PIT negative, 
with 63% recurrence rate
Functional corticotroph PAs were immunopositive for ACTH, SF-1, NeuroD1, 
T-PIT, but negative for DAX-1
GAs were immunopositive for SF-1, NeuroD1, DAX-1
Yunoue S. 
et al. [78] 2011 70
IHC
RT-PCR
Absence of co-expression of PIT-1, SF-1, NeuroD1 or chromogranin A with 
CD133 in PAs
CD133+ cells in PAs are involved in pituitary tumourigenesis as endothelial 
progenitors
Nishioka H. 






2/3 of the hormone negative PAs were positive for SF-1 and/or ERa 
(gonadotrophs were ¾ of NFPAs)
T-pit is a reliable marker of POMC-expressing pituitary cells
justifies the role of RT-qPCR T-PIT over hormones in determining the 
corticotroph origin of PAs
Mete O. 






All silent subtype 3 PAs were diffusely positive for PIT-1, most 
macroadenomas, high proportion associated with MEN1
Establishes the PIT-1 cell lineage origin of silent subtype 3 PAs and proposes 
the term “poorly differentiated PA of PIT-1 lineage”
Sjöstedt E. 





97.2% of PAs could be precisely classified into SF-1, PIT-1, and T-pit cell 
lineage PitNETs (7/246 null-cell PAs)
A specific T-pit antibody has a potential importance for tumours of 
corticotroph differentiation of non-pituitary origin
The anti-T-pit antibody is a reliable marker of corticotroph cell differentiation
Lee J. C. 




PIT-1 positivity is rare in previously classified null-cell PAs
Hormone-negative PAs of PIT-1 lineage are rare
PIT-1 can be useful in identifying sparsely granulated somatotroph PAs 
negative for GH
Nishioka H. 
et al. [81] 2017 128
PIT-1
SF-1
IHC SCAs and PIT-1 lineage silent adenoma are more aggressive than gonadotroph PAs
McDonald W. C. 




Significant positive correlation between PIT-1 and PRL, GH, TSH and 
significant negative correlation with SF-1
SF-1 correlated with FSH and LH staining
The routine use of FSH and LH can be replaced with SF-1 in IHC analysis of PAs
Mete O. 





40% surgically resected PAs are clinically NFPA, the majority being GAs
SF-1 is the most sensitive and specific factor for GAs
The incidence of null-cell PAs was only 4.5%
Langlois F. 






SCAs are aggressive, with recurrence rate of 36%
T-PIT disfunction can be an initial disturbance in the development of SCA
T-PIT is involved in phenotypic silence of SCAs
Compared to SGAs, SCAs recurred 3 times more often and had 6 times 
more often the need for radiotherapy
Torregrosa-Quesada 








RT-qPCR complements IHC and improves the typification of plurihormonal 
PIT-1 and unusual tumours
CAs expressed T-PIT and GATA2, GAs expressed GATA2 and NeuroD1
High concordance found: T-PIT, PIT-1, no concordance of SF-1
GATA-2 gene expression was concordant to SF-1 IHC expression
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PIT-1 tumours, and 45.44 years old for SF-1 tumours 
[15]. The incidence of gonadotroph tumours was found 
to rise with age, as well as the predominance of PIT-1 
lineage tumours in younger patients [16]. 
Histological evidence
Molecular considerations
Identifying the protein expression (by IHC) and the 
dominant gene (by qRT-PCR) of the pituitary tran-
scription factors gives the opportunity to classify and 
define different PA subtypes. Differences between 
real-time polymerase chain reaction (RT-PCR) and 
real-time quantitative reverse transcription PCR 
(qRT-PCR)results reflect the higher sensitivity of the 
latter methodology in samples expressing low tran-
script levels.
The pituitary adenohypophyseal tumour cytogen-
esis involves three lineages that require the presence 
of transcription factors for hormonal gene expression. 
The PIT-1 family is the most complex of all and con-
cerns somatotroph, lactotroph, mammosomatotroph, 
and thyrotroph cells. Despite the fact that PIT-1 mRNA 
transcripts are present in all pituitary cells, PIT-1 
protein is present only in these types of tumours. It 
gives rise to densely or sparsely granulated tumours, 
the poorly differentiated tumours of PIT-1 lineage 
arising from a PIT-1 stem cell. For development of 
gonadotroph cells and tumours the following are re-
quired: SF-1, ERa, GATA-binding protein 2 (GATA-2), 
Lhn4, and T-PIT and neurogenic differentiation fac-
tor 1 (NeuroD1) for corticotrophs, giving rise also to 
densely granulated, sparsely granulated, and Crooke 
cell corticotroph tumours [17]. Using the 2017 WHO 
Epidemiology 
Most pituitary tumours of adenohypophyseal cell dif-
ferentiation are benign and indolent (99.9%), the largest 
percentage being clinically inapparent and detected at 
autopsy. From all PAs discovered during lifetime, the 
prevalence of clinical significance is 1:1000 and from 
the ones that go to surgery, 10% manifest an atypical, 
NET-like behaviour (excepting prolactinomas, which 
are rarely treated neurosurgically) [8]. 
The prevalence of PAs increases with age, the peak 
age for diagnosis being 30–60 years, and some are 
associated with sex: female patients account for the 
majority of somatotroph and corticotroph PAs, while 
males for the majority of gonadotroph PAs, as found in 
a cohort of 250 pituitary tumours [12]. Also, regarding 
the paediatric population, boys have a more aggres-
sive forms of Cushing’s disease than girls [13]. In the 
above-mentioned cohort, the proportion of invasive 
high-risk adenomas was 28.8%, having a recurrence 
rate of 17.8% and for apoplexy of 8.2% [12]. 
Plurihormonal adenomas appear at a mean age of 
40.2 (± 12.5) years for PIT-1-positive ones, with female 
predominance, and 47.05 (± 16.4) years, with male 
predominance for the ones with unusual IHC combina-
tions, as reported recently. Their frequency, found by 
molecular study to be 3.6%, was observed to rise sub-
stantially by IHC analysis alone (12.5%) in a study [14].
In a total of 235 histologically confirmed PAs, PIT-1 
(59.09%) and T-PIT family tumours (58.18%) appeared 
more in females, in contraposition with SF-1 tumors, 
which were more frequent in males (58.57%) who pre-
sented with older age. Concerning age, the mean for 
T-PIT tumours was 58.73 years old, 42.87 years old for 
Table 1. Studies included in the review that evaluated at least thirty patients and their main disclosures
Study details Year No. of patients
Studied 
TFs Method Relevant findings
Tamanini J. V. G. 





PIT-1 positivity was highest in acromegaly patients
T-PIT positivity was higher in Cushing’s disease than acromegaly and NFPA
SF-1 did not differentiate NFPA from the other two groups
Turchini J. 





263 tumours were compared for GATA-3 and TFs expression
28% triple negative tumours, from which 64% had GATA-3 expression
GATA-3 positivity is found in most of the gonadotroph PAs and all thyrotroph 
PAs
Peng A. J. 





A machine learning model using preoperative T2-weighted MRI images can 
IHC classify PA subtypes, with an MRI-based radiomic analysis
SCAs and Crooke’s cell PAs are more aggressive and recurrent after surgery
TF — transcription factor; T-PIT — T-box family member TBX19; PIT-1 — pituitary specific POU class homeodomain transcription factor; SF-1 — steroidogenic 
factor 1; IHC — immunohistochemistry; RT-PCR — real-time polymerase chain reaction RT-qPCR — real-time quantitative reverse transcription PCR; PA — pituary 
adenoma; ACTH — adrenocorticotropin; NeuroD1 — neurogenic differentiation 1; DAX-1 — transcription factor product of the gene NR0B1; SCA — silent corticotroph 
adenomas; ER — estrogen receptor; NFPA —  non-functioning pituitary adenoma; POMC — pro-omiomelanocortin; PitNET — pituitary neuroendocrine tumors;  
GH — growth hormone; PRL — prolactin; TSH — thyroid-stimulating hormone; FSH —  follicle-stimulating hormone; SGA — silent gonadotroph adenomas;  
MRI — magnetic resonance imaging
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classification, < 5% of pituitary tumours are diagnosed 
as null cell adenomas [12].
In a subset of 56 patients from a large series of PAs 
(n = 251), a good correlation was demonstrated be-
tween immunohistochemistry and molecular detection 
of pituitary transcription factors, the concordance being 
high in immunopositivity and expression of T-PIT and 
PIT-1. The gene expression and immunodetection of 
SF-1 did not correlate, as opposed to the good concor-
dance found for GATA-2 [14]. This demonstrates the 
utility of RT-qPCR in complementing the IHC analysis, 
especially in null cell or plurihormonal tumours, and 
suggests that RT-qPCR should be added to routine 
clinical practice. In the same study, the incidence of null 
cell adenoma was reduced from 16.3% to 3.2% by using 
molecular studies of the specific TFs [14]. In several se-
ries, the percentage of null cell tumours decreased from 
12.7% to 7% and from 17% to 12.5% by using molecular 
analysis [18, 19].
Silent pituitary tumours are hormone-immunoreac-
tive tumours without clinical signs of hormone hyper-
secretion. In a cohort of silent somatotroph adenomas, 
they were more frequently sparsely granulated, with 
a lower percentage of immunoreactivity for growth 
hormone (GH), PIT-1, and SSTR2A than in acromegaly 
cases, suggesting the probability to be less differenti-
ated and having clinically “aggressive” behaviour [20]. 
As demonstrated, silent corticotroph adenomas and 
the ones with PIT-1 positivity are more aggressive than 
silent gonadotroph adenomas [21].
Null cell adenomas are immunonegative for both 
hormones and TFs of anterior pituitary development. 
Although IHC is negative for all hormones, they have 
organelles for hormone synthesis and release, and 
some can produce glycoprotein subunits in vitro, thus 
sustaining the supposition of resemblance with silent 
gonadotroph adenomas [22]. Assessing 147 pituitary 
adenomas immunonegative for GH, prolactin (PRL), 
adrenocorticotropin (ACTH), and thyroid-stimulating 
hormone (TSH), 46% expressed SF-1. Of the other 
cases, 6% were positive for PIT-1, the other cases 
being potential null cell adenomas [23]. In a series of 
1071 surgically treated pituitary adenomas, null cell 
tumours (0.6%) represented 5% of hormone-negative 
adenomas, 1.2% of non-functioning pituitary adenomas 
(NFPA), with a poor ultrastructural differentiation and 
aggressive clinical and neuroimaging aspects [24].
Although about 40% of surgically resected pituitary 
tumours are NFPAs, the majority are identified as of 
gonadotroph lineage [16]. However, as reported by the 
EPPG experts, about 15–20% of PAs have a limited/ab-
sent/unusual pituitary hormone expression. In such 
cases, chromogranin A and TFs are useful for defining 
the pituitary neuroendocrine origin and to classify some 
of them in corticotroph, gonadotroph, or plurihormonal 
PIT-1-positive PAs [9, 10].
Another part played by the TFs is enlightening the 
histopathological terminology of hyperplasia. Along 
with reticulin, TFs can help in distinguishing the pitu-
itary hyperplasia from ectopic secretion of GHRH or 
CRH or that secondary to primary hyperthyroidism [25].
T-PIT
T-PIT is a T-box factor found in the two pituitary 
pro-opiomelanocortin (POMC) lineages, the melano-
trophs, and corticotropes, and it can initiate differen-
tiation into POMC-expressing lineages [26]. There is 
a strong correlation between mRNA expression of T-PIT 
and POMC in Cushing’s disease (especially due to mac-
roadenomas), but also in silent corticotroph adenomas 
[27]. T-PIT, along with NeuroD1, plays a very important 
role in the differentiation of corticotroph lineage and 
transcription of POMC gene, and both are required to 
achieve corticotroph differentiation (through interac-
tion with Pitx1) in pituitary and non-pituitary tumours 
[28]. Cooperating with these two, Nur77 (nerve growth 
factor-inducible factor-B) also induces POMC expres-
sion, in some cases being the only factor to differentiate 
subclinical Cushing’s disease from Cushing’s disease, 
as demonstrated in a comparative study that included 
13 ACTH-secreting adenomas [29].
Although NeuroD1 is considered corticotroph spe-
cific, it is overexpressed also in some non-corticotroph 
pituitary adenomas, possible due to the activation of 
molecular factors such as neurogenins. In a study on 51 
pituitary adenomas, NeuroD1 expression was higher in 
corticotroph and NFPA, while neurogenin 2 expression 
was higher in PIT-1-dependent pituitary adenomas, 
especially in those with pre-operative pharmacological 
treatment [30]. Compared to T-PIT, which can be con-
sidered a marker of corticotroph tumours, NeuroD1 has 
poor discriminatory usefulness [14]. 
A study comparing 13 patients with Cushing’s 
disease with 4 carcinoid tumours with ectopic ACTH 
secretion revealed that there is no difference on the 
expression of T-PIT and NeuroD1 between these two 
entities and they are also expressed in ACTH-negative 
carcinoid tumours, indicating that some other transcrip-
tion factors can be involved in inducing POMC mRNA 
in ectopic ACTH-secreting tumours [28]. 
T-PIT family tumours occur with higher frequency 
in females, the mean age ranging from 23 to 75 years, 
and they are more frequently associated with grade 0–2 
lesions, as observed by Peng et al. [15].  Cushing disease 
patients have the highest nuclear expression of T-PIT 
(versus acromegaly and NFPA) [31]. Most corticotroph 
cell adenomas belonging to the ACTH/POMC lineage 
are mono-hormonal [32].
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Because of the lack of reliable T-PIT antibody, tu-
mours that express this transcription factor are still 
difficult to diagnose; thus, combining IHC analysis with 
preoperative magnetic resonance imaging (MRI) coro-
nal T2-weighted images adds precision to the diagnosis 
and classification [15].
Silent corticotroph adenomas (SCA) are tumours 
with clinical and morphological features of both corti-
cotrope and gonadotroph adenomas. In a study con-
ducted by Cooper et al., although they expressed ACTH 
to a similar degree as functional corticotroph adeno-
mas, clinically they behaved more like an NFPA [33]. 
They lack T-PIT expression, but incorporate cortico-
troph markers ACTH and NeuroD1 and gonadotroph 
markers SF-1, alpha subunit of glycoprotein hormones 
(alpha-GSU) and DAX-1 [33]. In a large cohort of 814 
surgically resected PAs, only 4.8% (39) were SCA and 
had similar tumour size and invasiveness compared 
to silent gonadotroph adenomas (SGA), but the first 
ones were three-times more aggressive. They have 
a special potential to change their phenotype in time, 
and their phenotypic silence is related to T-PIT, its dys-
functionality probably being a precocious abnormality 
in a SCA [34]. 
In 43 out of 283 cases, the application of the three 
transcription factors by IHC revealed the specific diag-
nosis. In the same cohort, there were a significant num-
ber of triple-negative tumours (28%, without hormonal 
or transcription factor expression) that showed GATA-3 
expression, strongly indicating a gonadotroph or thy-
rotroph lineage [35]. Some corticotroph tumours also 
express GATA2, as well as some gonadotroph tumours, 
which express NeuroD1, this co-expression suggesting 
the existence of a cortico-gonadotroph entity that also 
expresses SF-1, but little or no T-pit, and clinically be-
having like silent corticotroph adenomas [14].
In a cohort of 24 patients with pituitary tumours, 
T-PIT expression in corticotroph tumours was 27-fold 
higher than in controls. The expression of T-PIT had 
a constitutive pattern in somatotropinomas and a het-
erogeneous one in NFPA, respectively [36].
Regarding therapy, the effect of R-roscovitine on 
corticotroph tumours in a recent study showed that it 
inhibits POMC and T-PIT by targeting the cyclin E/E2F1 
pathway, with decreased ACTH expression, thus being 
a therapeutic pathway in Cushing disease as an inhibi-
tor of cyclin-dependent kinase 2 [37]. USP8-mutated 
corticotroph PAs showed higher SSTR5 expression, 
which helps in the prediction of response to somatosta-
tin analogue pasireotide [38].
PIT-1
The role of PIT-1 in cytodifferentiation was acknowl-
edged when PIT-1 gene expression was found to be 
closely related to the production of GH, PRL, and/or 
TSH in pituitary development [39]. 
PIT-1, a member of the POU-domain family, is 
a nuclear transcription factor involved in the normal 
differentiation and growth of somatotroph, mam-
mosomatotroph, lactotroph, and thyrotroph cells, as 
well as in the abnormal cell proliferation of pituitary 
adenomas, PIT-1 protein being highly correlated with 
IHC tumour staining for GH, TSH, and PRL [40]. PIT-1 
is expressed after Prophet of PIT-1 (PROP1) during 
embryogenesis and is maintained in the adult pituitary 
somatotropes, lactotropes, and thyrotropes [41]. PROP1 
showed overexpression in tumour pituitary samples, 
18-fold higher in corticotropinomas, 10-fold higher 
in somatotropinomas, and 3-fold higher in NFPA, 
although PROP1 is not associated with corticotroph 
differentiation but in maintaining the cells implicated 
in corticotroph differentiation [36]. 
A recent molecular classification of PAs using somat-
ic, chromosomal alterations and miRNome, methylome, 
and transcriptome combined identified PIT-1 lineage as 
the main separator/classification driver in a total of 134 
included patients. The PIT-1 lineage was associated with 
transcription of different markers and chromosomal 
instability [38].
Somatotroph cells are the only pituitary secre-
tory cell expressing GDNF family receptor alpha-1 
(GFRa1), glial cell line-derived neurotrophic factor 
(GDNF), and Ret, the last inducing PIT-1 and p53 
over-expression, a pattern that is maintained in all 
somatotroph adenomas [42, 43]. For a precursor cell 
to become somatotroph, it requires PIT-1, and for suf-
ficient PIT-1 expression, Ret is needed. Ret-induced 
PIT-1 over-expression determines apoptosis of aberrant 
somatotrophs, this explaining the fact that somatotropi-
nomas have a normal Ret/GFRa1 and GDNF expression 
and do not metastasize [43].
By definition, somatotroph tumours have nuclear 
positivity for PIT-1 and cytoplasmatic GH positivity. 
Oestrogen receptor positivity in these tumours cor-
relates with prolactin positivity. Poorly differentiated 
tumours of PIT-1 lineage (the former silent subtype 3 
adenoma) express PIT-1 and a variable expression of 
GH, PRL, ER, or a-subunit [16]. 
In some of the first pituitary adenoma series stud-
ied by RT-PCR, a quantitative difference from normal 
pituitary tissue, with correspondence to sequencing of 
PIT-1 DNA in prolactinomas was not demonstrated, 
which revealed no mutation compared to normal pitu-
itary tissue [44, 45]. In other studies, PRL/GH-secreting 
adenomas and GH- and PRL-secreting adenomas had 
a 2.5- to 5-times higher PIT-1 expression. PIT-1 was 
fond to be identical in size in normal pituitary and the 
above-mentioned adenomas, when it is overexpressed 
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to an extent correlated with the predominant cellular tu-
moral type [45]. PIT-1 gene expression was also found in 
NFPA, one explanation being the ability of stem cells to 
differentiate towards any of the three phenotypes [46].
In a subset of prolactinomas, a somatic mutation 
in splicing factor 3 subunit B1 was found to correlate 
with a stronger binding of PIT-1, which leads to exces-
sive prolactin secretion, higher prolactin levels, and 
shorter progression-free survival [47]. In functioning 
prolactinomas, PIT-1 mRNA expression tends to be 
high, with a low GHRH-R mRNA expression, unlike 
the positive correlation found in functioning somato-
troph adenomas. In the silent variants of both of these 
tumours, the levels of PIT-1 and GHRH-R are similar 
to the corresponding functional ones [48].
Known for their versatile clinical behaviour, 
TSH-producing pituitary adenomas range from typical 
to clinically silent, indicating the importance of ad-
equate IHC analysis. In a subset of TSH-secreting pi-
tuitary tumours (silent macroadenomas and functional 
PA), all had the same histopathological features. PIT-1 
was detected by immunostaining in 16 out of 18 func-
tional tumours and in 9 of 10 of the silent ones, with 
GATA-2 co-expression in almost all (by IHC and/or 
RT-PCR). PIT-1 and GATA-2 expression did not cor-
relate with age, tumour size, invasive character, or the 
level of TSH, but both were detected in all silent and 
two of the functional adenomas. No correlations were 
found between Ki-67 index, PIT-1, GATA-2, SSTR2A, and 
SSTR5 [49]. Thyrotroph tumours are monohormonal and 
plurihormonal, the latter co-expressing GH or PRL, 
both expressing high levels of PIT-1 and SSTR2A, with 
a predominance of clinical hyperthyroidism signs in 
the plurihormonal ones [50]. TSH-secreting adenomas 
may originate from early totipotent progenitor cells 
from which derive GH-, PRL-, and TSH-secreting cells, 
a mechanism that can be part of the plurihormonality 
of these tumours [51].
Plurihormonal pituitary tumours are divided into 
tumours with PIT-1 positivity and tumours with un-
usual immunohistochemical combinations (without 
a determinant transcription factor). They can be identi-
fied only by pathologic assessment and have an aggres-
sive behaviour in about 55.5% of cases. The latter arise 
from different pituitary cell lineages. The PIT-1-positive 
plurihormonal adenomas (previously known as silent 
subtype 3 adenomas, although a criticised analogy) 
have a variety of focal-scattered immunoreactivity for 
GH, PRL, and TSH (the PIT-1 lineage hormones), usu-
ally clinically presenting as NFPAs, a few cases having 
clinical expression of GH or PRL secretion [52]. PAs that 
belong to the PIT-1 family often have an overexpres-
sion of alpha subunit, but this characteristic does not 
necessary classify them as being plurihormonal [53].
Multiple PAs comprise two or more distinct tumours 
with different pituitary cell types, with low incidence 
(0.4–1.3%) [53].  In a series of 1055 pituitary adenomas, 
13 had synchronous multiple tumour components 
(1.2% of cases), 12 were double and one was triple. 
The triple association had an unusual plurihormonal 
tumour, which was positive for GH, gonadotropin 
(FSH), PIT-1, and SF-1, along with two other smaller 
tumours: a sparsely granulated lactotroph PIT-1 and 
ER-positive and a gonadotroph tumour positive for 
SF-1 and FSH, but negative for PIT-1 and GH. In all 
cases, the aggressive histological subtypes predicted the 
potential of recurrence and of persistent disease [54]. 
The highest incidence of plurihormonality has been 
found in PIT-1-positive tumours [16]. 
Regarding SSTR, SSTR3 expression is higher in 
corticotroph adenomas compared to PIT-1 positive, 
gonadotroph, and NFPAs. SSTR5 expression is highest 
in PIT-1-positive adenomas, followed by corticotroph, 
gonadotroph, and NFPAs. When comparing primary 
to recurrent adenomas, SSTR2A, SSTR3, and SSTR5 are 
lower in recurrent PIT-1-positive pituitary adenomas 
when compared to the primary group [55].
Silent adenomas of PIT-1 lineage tend to be more 
common in the young and have a higher Ki-67 index, as 
found by a study on NFPAs. In the same study, 4 out of 5 
patients with silent PIT-1 adenomas with incomplete tu-
mour resection underwent adjuvant radiotherapy [56].
PIT-1-positive silent pituitary adenomas (indicating 
differentiation into somatomammothyrotroph family) 
and silent corticotroph adenomas have a more ag-
gressive behaviour than gonadotroph adenomas [57], 
as well as giant adenomas, which tend to be resistant 
to surgical treatment and have a high incidence of 
recurrence, features more common in the mentioned 
histological subtypes [58].
SF-1
Steroidogenic factor 1 (SF-1) is expressed in gonado-
troph cells, leading to their differentiation [59], as well 
as in gonadotroph PAs, acting also in the adrenals and 
reproductive system [60]. Using IHC for SF-1 in diag-
nosing tumours of gonadotroph lineage, the incidence 
of ‘null cell’ pituitary adenomas dropped to around 
1% [61].
In a cohort of 30 pituitary adenomas, the frequency 
of SF-1 immunopositive cellularity was similar in all 
tumours. SF-1 can be detected along with PIT-1 or T-
PIT in patients with acromegaly, Cushing’s, or NFPA, 
leading to the idea of co-expression of TFs [31]. 
In a recent study, functional tumours proved to be 
the least common among SF-1 family tumours (8.47%), 
these being diagnosed with the highest frequency in 
PIT-1 family tumours (74.55%). The tumours with the 
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largest diameter and those with grade 3–4 had greater 
frequency in SF-1 family tumours compared to the ones 
with grade 0–2, which were more frequent in PIT-1 
and T-PIT family tumours [15]. In another cohort (1055 
adenohypophyseal tumours), gonadotroph tumours 
stained positive for SF-1 in 96% of cases, while ER was 
positive in 82% [16]. 
Among 89 cases of corticotroph PAs, all were im-
munopositive for SF-1 and DAX-1. ACTH immunos-
taining was localised in cytoplasm, whereas SF-1 and 
GATA-2 were positive in the nuclei. Expression of SF-1, 
DAX-1, and GATA2 was localised in the a-subunit im-
munopositive cells, but also diffusely in all tumour 
tissues. In a subset of 39 cases from the same cohort, 
immunopositive for only ACTH, all were immunonega-
tive for SF-1 and GATA-2, which do not belong to ACTH 
cell lineage [32].
Unexpectedly, the gonadotroph subset of a pituitary 
tumour series expressed similar levels of SF-1 as other 
PitNET subtypes. Nonetheless, 36.62% of all gonado-
troph tumours expressed SF-1 and SF-1 protein, with 
an expression of GATA2 of 87.32% [14].
In case of triple-negative tumours expressing FSH 
and LH or ambiguous SF-1 staining, GATA-3 can be 
an important indicator of thyrotroph or gonadotroph 
lineage [35].
In a recent molecular classification that analysed 
molecular classes of PAs by integrated pangenomics 
found gonadotroph signatures in some corticotroph 
and somatotroph PAs (GNAS-wild-type somatotrophs 
with SF1 expression), raising a challenge to the current 
SF1 lineage tumours and the specificity of this SF-1 for 
the gonadotroph lineage [38]. This raises a question 
about the presence of occasional tumours (collision tu-
mours with different lineages) [54], for the presence of 
trapped non-tumorous tissue in the samples used [25], 
or for a questionable specificity of the SF-1 lineage [38].
Aggressivity 
In PAs, as in all tumours of the central nervous system, 
a stem gene profile of tumour-initiating cells has been 
identified, which promote growth and tumour progres-
sion [62]. 
In defining aggressive behaviour, the algorithm 
should be based on clinical behaviour, neuroradiologi-
cal features, growth rate, and response to treatment. 
Aggressive pituitary tumours are large (many are giant, 
over 4 cm diameter), invasive (Knosp grades 3 or 4, 
with invasion of the sphenoid sinus), have high growth 
rates (> 20% and at least 2 mm in 6 months), and resist 
standard medical treatment (> 20% growth despite 
surgical, medical, and radiotherapeutic care) [63, 64]. 
Invasion should be evaluated pre-operatively 
(MRI), intra-operatively (endoscopic examination), 
and post-operatively, with Ki-67 (≥ 3%) and mitotic 
count > 2/10 HPF. P53 is an independent marker of 
aggressivity and can aid in the diagnosis [65], but 
only 40% of reports describe a predictive role of this 
marker regrading invasiveness (comparing to 62% 
positive correlation for Ki-67) [66]. In several works, 
the histological proof of invasiveness (infiltration of the 
adjacent dura) is a more frequent finding than in the 
surgical evaluation [67, 68]. In a large series of patients, 
the plurihormonal PAs were the majority (92%) with 
a Ki-67 of < 3% [53]. 
As it is known, the entity “atypical adenoma” was 
removed in the 2017 WHO classification, and replaced 
to the ‘high-risk adenoma’, and some PA subtypes are 
seen as aggressive: lactotroph adenoma in men, sparse-
ly granulated somatotroph adenoma, silent corticotroph 
adenoma, Crooke cell adenoma, and plurihormonal 
PIT-1 positive adenoma [69]. Excluding the first entity, 
which is demonstrated to be aggressive, the other ones 
are still under confirmation [70].
In AIP-positive PAs (isolated or syndromic) or those 
from MEN1 or MEN4 syndromes, tumour aggressive-
ness, larger dimensions, and resistance to conven-
tional treatment has been reported, especially related 
to disruption of mesenchymal-to-epithelial transition 
[66, 71]. Other syndromic causes of PAs include Car-
ney complex (PRKAR1A/PRKACB), McCune-Albright 
(GNAS), HPGL (SDHx, MAX), Dicer (DICER1), Lynch 
(MLH1, PMS2), or USP8-related (USP8) syndromes 
[72]. In several studies, only 2 genes (GNAS and 
USP8) were found mutated in >5% of PAs, no other 
driver alteration being found for the majority of Pit-
NETs. USP8-mutated  corticotroph PAs represent 
a group with limited aggressiveness (compared to 
USP8 wild-type PAs) [38, 73].
The exact differences between aggressive PAs and 
carcinomas are not very well defined and can be two 
sides of the same coin. After corticotroph PAs, lactotroph 
ones are the second most-frequent aggressive and 
malignant [74, 75]. Considering the results of different 
studies, a Ki-67 over 10% can be considered a marker of 
malignancy, but not taken per se [70]. Although useful 
in classifying PAs, pituitary transcription factors alone 
are not routinely used for the assessment of aggres-
siveness [64].
Conclusions and future perspectives
Along with hormone assessment, the routine use of 
pituitary transcription factors (PIT-1, SF1, TPit) in the 
immunohistochemical analysis of pituitary tumours 
should be a habit in current practice for a precise di-
agnosis and avoidance of a misleading one. Their role 
in pituitary cytodifferentiation and tumourigenesis is 
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clarified. Although most pituitary adenomas are mainly 
classified with immunohistochemistry staining for pitu-
itary hormones, transcription factor immunostaining is 
important in special cases with doubtful differentiation, 
such as null-cell or plurihormonal adenomas. 
The present review provides important informa-
tion to support the utility of these transcription factors 
in establishing the origin of the pituitary adenomas 
and differentiating them from other pituitary entities, 
such as mesenchymal, stromal, or neuronal pituitary 
tumours. 
The biological relevance and importance of pituitary 
transcription factors was stated by the WHO in 2017, 
but also by novel extensive molecular classifications, 
a bridge between the two being the goal in future man-
agement. Their immunohistochemical and molecular 
study has prognostic value confirmed by several studies 
on large cohorts of patients. Their analysis could also 
be useful in predicting the response to treatment and 
the tumour changes that can have important clinical 
consequences. Hence, specific analysis of pituitary ad-
enomas should be integrated into the clinical context, 
with a multidisciplinary approach. 
The grading of the aggressive behaviour of pituitary 
tumours is still under study and requires proliferative 
markers and complete immunodetection staining, the 
final diagnosis combining the first two with the clinical 
and radiological aspects, to correctly treat these unpre-
dictable tumours.
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